Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Overview of attention for article published in JACC: Heart Failure, April 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 15 X users

bluesky: 5 Bluesky users

Readers on

mendeley: 20 Mendeley

So far, Altmetric has seen 18 X posts from 15 X users, with an upper bound of 164,525 followers.

RT @JACCJournals: In this cohort of patients with symptomatic #oHCM with persistent #LVOT obstruction, combination therapy with #aficamten…

In this cohort of patients with symptomatic #oHCM with persistent #LVOT obstruction, combination therapy with #aficamten and #disopyramide was safe and well tolerated but did not enhance clinical efficacy vs aficamten alone. https://t.co/3wZ0N2EC8N #JAC…

RT @jpcostabel: Buen análisis de @MasriAhmadMD en @JACCJournals. ➡️Disopiramida no parece agregar beneficio cuando aficamten funciona en p…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 14 additional X posts.